Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma ...

These five quality blue-chip stocks should pay a higher dividend than a high-yield money market after Federal Reserve ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its patents for the drug, which is used to treat multiple myeloma, a blood cancer ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Legacy Portfolio is being adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect.

These five well-run companies with stocks that yield at least 5% have strong dividend coverage and look like timely buys now.

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.